Comparison · NCT03614728-sae
Part 1: GSK3326595 400 mg vs Part 1: GSK3326595 300 mg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Part 1: GSK3326595 400 mg vs Part 1: GSK3326595 300 mg: serious adverse events. Trial comparisons, record NCT03614728-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03614728-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.846 | 0.578 | 0.957 | wilson | |
| Risk in group 2 | 0.706 | 0.469 | 0.867 | wilson | |
| Risk difference, group 1 minus group 2 | 0.14 | -0.173 | 0.402 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.2 | 0.816 | 1.76 | log | |
| Odds ratio, group 1 over group 2 | 2.29 | 0.367 | 14.3 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Part 1: GSK3326595 400 mg than on Part 1: GSK3326595 300 mg | 7.13 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Part 1: GSK3326595 400 mg | Participants received GSK3326595 400 mg, tablets, orally, once daily until progression, unacceptable toxicity, or withdrawal of consent during Part 1 of the study. | 11 | 13 | EG000 |
| Group 2 | Part 1: GSK3326595 300 mg | Participants received GSK3326595 300 mg, tablets, orally, once daily until progression, unacceptable toxicity, or withdrawal of consent during Part 1 of the study. | 12 | 17 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- All-cause mortality, common non-STEAEs and STEAEs were collected up to 30.8 months in Part 1 of the study
Source ClinicalTrials.gov
Trial
- Title
- Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
- NCT number
- NCT03614728
- Phases
- PHASE1, PHASE2
- Conditions
- Neoplasms
- Interventions
- GSK3326595, 5-Azacitidine
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2023-02-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03614728?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03614728-sae